Elizabeth R Plimack, MD, MS
Bajorin DF et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384(22):2102-14. Abstract
Balar AV et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22(7):919-30. Abstract
Friedlander TW et al. Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma. ASCO 2021;Abstract 4528.
Galsky MD et al. Primary analysis from DS8201-A-U105: A phase 1b, 2-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). ASCO Genitourinary Cancers Symposium 2022;Abstract 438.
Galsky MD et al. Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study. ASCO Genitourinary Cancers Symposium 2021;Abstract 434.
Grivas P et al. TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. ASCO Genitourinary Cancers Symposium 2022;Abstract 434.
O’Donnell PH et al. First-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. ASCO 2021;Abstract 4508.
Petrylak DP et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. ASCO Genitourinary Cancers Symposium 2022;Abstract 435.
Powles T et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): A randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(7):931-45. Abstract
Powles T et al. Avelumab maintenance in advanced urothelial carcinoma: Biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat Med 2021;27(12):2200-11. Abstract
Powles T et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125-35. Abstract
Sheng X et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res 2021;27(1):43-51. Abstract
Siefker-Radtke AO et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: Long-term follow-up of a phase 2 study. Lancet Oncol 2022;23(2):248-58. Abstract
Tagawa ST et al. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39(22):2474-85. Abstract
Yu EY et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): A multicentre, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):872-82. Abstract
Thomas Powles, MBBS, MRCP, MD
Choueiri TK et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. ASCO Genitourinary Cancers Symposium 2022;Abstract 290.
Choueiri TK et al. A phase 3 trial of lenvatinib plus pembrolizumab (len+pembro) versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma (aRCC): Overall survival follow-up analysis (CLEAR study). International Kidney Cancer Symposium 2021;Abstract E41.
Choueiri TK et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021;385(8):683-94. Abstract
Choueiri TK et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829-41. Abstract
Haanen JB et al. Efficacy of avelumab + axitinib (a + ax) versus sunitinib (s) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. ASCO 2021;Abstract 4574.
Jonasch E et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med 2021;385(22):2036-46. Abstract
McDermott DF et al. Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma. J Clin Oncol 2021;39(9):1029-39. Abstract
McDermott DF et al. Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2-alpha (HIF-2-alpha) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC). ESMO 2021;Abstract 656MO.
Motzer RJ et al. Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (n + i) versus sunitinib (s) in advanced RCC (aRCC). ESMO 2021;Abstract 661P.
Motzer R et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 2021;384(14):1289-300. Abstract
Pal SK et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: A randomised, open-label, phase 2 trial. Lancet 2021;397(10275):695-703. Abstract
Pal SK et al. Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: Results from the COSMIC-021 study. J Clin Oncol 2021;39(33):3725-36. Abstract
Porta CG et al. First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial. ESMO 2021;Abstract 663P.
Powles T et al. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer 2021;21(1):904. Abstract
Rini BI et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. ASCO 2021;Abstract 4500.
Verzoni E et al. TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC). ASCO 2021;Abstract 4546.